Evidence map›Paper›PMID 30915878›Full record

ArticleJournal of the renin-angiotensin-aldosterone system : JRAAS

The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers.

Michio Fukuda, Yukako Isobe-Sasaki, Ryo Sato, Toshiyuki Miura, Masashi Mizuno, Minamo Ono, Ken Kiyono, Yoshiharu Yamamoto, Junichiro Hayano, Nobuyuki Ohte

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the renin-angiotensin-aldosterone system : JRAAS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michio Fukuda1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.ORCID https://orcid.org/0000-0002-7455-5776
Yukako Isobe-Sasaki1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.
Ryo Sato1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.
Toshiyuki Miura1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.
Masashi Mizuno1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.
Minamo Ono1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.
Ken Kiyono2 Department of Mechanical Science and Bioengineering, Osaka University, Japan.
Yoshiharu Yamamoto3 Department of Physical and Health Education, University of Tokyo Graduate School of Education, Japan.
Junichiro Hayano4 Department of Medical Education, Nagoya City University Graduate School of Medical Sciences, Japan.
Nobuyuki Ohte1 Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Japan.
Nagoya City University · JPJapan Graduate School of Education University · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective: In our recent study, non-Gaussianity of heart rate variability (λ

methods: In this subanalysis, 20 patients with chronic kidney disease (14 men; age 61±15 years) were divided into three groups: patients with coadministration of L-type CCB, patients without coadministration of CCB, and patients with coadministration of sympathoinhibitory (L/T- or L/T/N-type) CCB. λ

results: Daytime λ

conclusions: CCBs, as well as diuretics, are recommended as second-line antihypertensive agents. Our results suggested that ARBs can overwhelm the activation of sympathetic nerve activity stimulated by coadministration of L-type CCBs.

Indexed as

Angiotensin II Type 1 Receptor BlockersBenzimidazolesCalcium Channel BlockersFemaleHumansMaleMiddle AgedOxadiazolesSympathetic Nervous SystemAngiotensin II Type 1 Receptor BlockersazilsartanBenzimidazolesCalcium Channel BlockersOxadiazolesAngiotensin receptor blockercalcium channel blockerchronic kidney diseaseheart rate variabilitysympathetic nerve activity

Identifiers

PMID30915878
PMCPMC6437324
OpenAlexW2923737498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.